News Focus
News Focus
icon url

attilathehunt

07/31/22 8:46 PM

#368436 RE: Steady_T #368435

I wonder if any of the analyst will revise their price targets with this latest info!
icon url

crescentmotor

07/31/22 9:16 PM

#368448 RE: Steady_T #368435

Because your suggestion is short sighted and doesn't reflect what is believed by many on the board to be the true value of Anavex.



Of course, you are entitled to that opinion. The fact remains that many biotech companies do a cautionary capital raise in front of late-stage trial binary events. It happens more times than not to assure company survival in the event of a failed Phase III. That is known as executive fiduciary responsibility. Sometimes, that hedge even goes past a secondary offering. Arena Pharmaceuticals just sold out to PFE in front of what turned out to be a highly successful Phase III trial of its drug for ulcerative colitis and Chron's Disease.

I'm not suggesting that Anavex do a partnership although I would not be disappointed in a ROW partnership under great terms or a modest capital raise. It all depends on Dr. Missling's confidence in all the data that is known to him over the years in the indications Anavex is targeting.